Registration
Advertiser Disclosure

Merck KGaA (MRK.DE) News and Global Science & Technology Innovation Updates

Merck KGaA, headquartered in Darmstadt, Germany, is a multinational science and technology company with operations in healthcare, life sciences, and performance materials (electronics). Its businesses include pharmaceuticals, laboratory supplies, and specialty chemicals for electronics and semiconductors. Merck is focused on research-driven innovation in oncology, immunology, bioprocessing, and next-generation electronics.

143.45
2.9000
1.98 %
At close 10/23
EUR
EUR
XETRA
Daily range
142.75 Arrow from to Icon 146.00
Weekly range
141.85 Arrow from to Icon 147.55
Live Price Short-Term Long-Term Signals Earnings Dividends Price History News
Merck announces positive Phase 3 data for neoantigen therapy: Can MRK break above $149.98?
  • Andrey Mastykin
  • Yesterday
Merck announces positive Phase 3 data for neoantigen therapy: Can MRK break above $149.98?
Merck said it has posted positive Phase 3 results for its neoantigen therapy combined with its immunotherapy for resected stage IIB-IV melanoma, developed in partnership with Moderna. Shares edge ...
Merck announces topline results from Phase 2b/3 study in diabetic macular edema after stock ends session down 1.8%
  • Sergey Shendetskyi
  • 24.09.2026
Merck announces topline results from Phase 2b/3 study in diabetic macular edema after stock ends session down 1.8%
Merck announced topline results from a pivotal Phase 2b/3 study of its investigational therapy in diabetic macular edema on September 3, 2026. The stock is down 1.8% on the day at $148.1.Merck ...
Merck stock holds above key technical levels after FDA RSV filing news
  • Jainam Mehta
  • 06.08.2026
Merck stock holds above key technical levels after FDA RSV filing news
Merck said the FDA has accepted its filing related to RSV disease in a post on its official account. At the same time, Merck stock edges higher on the day, trading at $128.34.The company itself ...
Merck stock drops 1.85 percent to $127.80 as shares test key Kijun support
  • Jose Antonio Gastelum
  • 04.08.2026
Merck stock drops 1.85 percent to $127.80 as shares test key Kijun support
Merck is inviting investors to join its second quarter 2026 earnings call at 9 a.m. ET today. At the same time, Merck stock is down 1.8% on the day at $127.8.The Merck corporate account announced ...
Merck stock slips 1.85 percent to $127.80 as shares test key support at $127.61
  • Parshwa Turakhiya
  • 04.08.2026
Merck stock slips 1.85 percent to $127.80 as shares test key support at $127.61
Merck posted its second quarter 2026 earnings results on social media. At the same time, Merck stock is down 1.8% on the day at $127.8.Merck, via its official account, announced that its Q2 2026 ...
Merck edges higher to $125.22 as company unveils new Phase 3 HIV data with Gilead partnership
  • Jainam Mehta
  • 21.07.2026
Merck edges higher to $125.22 as company unveils new Phase 3 HIV data with Gilead partnership
Merck is presenting new data at AIDS 2026 from its Phase 3 trials of an investigational, once-weekly oral HIV treatment for adults with virologically suppressed HIV.Merck is collaborating with ...
Merck stock jumps 2.31% as company expands HIV treatment access through ADAPs
  • Ciaran Ryan
  • 29.06.2026
Merck stock jumps 2.31% as company expands HIV treatment access through ADAPs
Merck announced an agreement with the AIDS Crisis Task Force to provide increased access to HIV treatment for eligible people living with HIV through state AIDS Drug Assistance Programs.The ...
Merck stock slides amid strong selling pressure despite Phase 3 immunology trial update
  • Jose Antonio Gastelum
  • 22.06.2026
Merck stock slides amid strong selling pressure despite Phase 3 immunology trial update
Merck reported positive topline results from a Phase 3 induction-only study in patients with moderately to severely active ulcerative colitis.The company stated these results reinforce its ongoing ...
Merck stock drops 1.25% as company posts strong Phase 3 HIV data with Gilead Sciences
  • Ezequiel Gomes
  • 09.06.2026
Merck stock drops 1.25% as company posts strong Phase 3 HIV data with Gilead Sciences
Merck announced positive topline Phase 3 results for its investigational once-weekly HIV treatment for adults with virologically suppressed HIV.The results come from a collaboration with Gilead ...
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers